Randomized phase III trial of ipatasertib vs. placebo, plus abiraterone and prednisone/prednisolone, in men with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer (mCRPC)

被引：0
|
作者：
de Bono, J. [1 ,2 ]
Bracarda, S. [3 ,4 ]
Chi, K. [5 ]
Massard, C. [6 ]
Olmos Hidalgo, D. [7 ]
Sandhu, S. [8 ]
Sternberg, C. N. [9 ]
Gendreau, S. [10 ]
Xu, N. [11 ]
Baney, T. [12 ]
Maslyar, D. [13 ]
Sweeney, C. J. [14 ]
机构：
[1] Inst Canc Res, Div Clin Studies & Expt Med, London, England
[2] Royal Marsden Hosp, London, England
[3] ITT, Azienda USL Toscana Sud Est, Dept Oncol, Med Oncol, Arezzo, Italy
[4] Osped San Donato, Arezzo, Italy
[5] BC Canc Agcy, Clin Trials Unit, Vancouver, BC, Canada
[6] Inst Gustave Roussy, Early Drug Dev Dept, Villejuif, France
[7] Spanish Natl Canc Res Ctr, Prostate Canc Clin Res Unit, Madrid, Spain
[8] Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[9] San Camillo & Forlanini Hosp, Dept Oncol, Rome, Italy
[10] Genentech Inc, Late Stage Biomarker Dev, San Francisco, CA 94080 USA
[11] Genentech Inc, Biostat Oncol Solid Tumor, San Francisco, CA 94080 USA
[12] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[13] Genentech Inc, Prod Dev Clin Oncol, San Francisco, CA 94080 USA
[14] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
834TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase 2 trial of sipuleucel-T in combination with concurrent or sequential abiraterone acetate (AA) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Small, E.
    Lance, R.
    Gardner, T. A.
    Karsh, L. I.
    Stubbs, A.
    McCoy, C.
    DeVries, T.
    Redfern, C. H.
    Shore, N. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S682 - S683
  • [32] ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)
    Smith, M. R.
    Parker, C. C.
    Saad, F.
    Miller, K.
    Tombal, B.
    Ng, Q. S.
    Boegemann, M.
    Matveev, V.
    Piulats, J. M.
    Zucca, L. E.
    Heidenreich, A.
    Kakehi, Y.
    Zhang, A.
    Krissel, H.
    Shen, J.
    Wagner, V.
    Higano, C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC)
    Shi, Zhen
    Sweeney, Christopher
    Bracarda, Sergio
    Sternberg, Cora N.
    Chi, Kim N.
    Olmos, David
    Sandhu, Shahneen Kaur
    Massard, Christophe
    Matsubara, Nobuaki
    Harle-Yge, Marie-Laurence
    Nowicka, Malgorzata
    Wongchenko, Matthew
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
    Michaelson, M. Dror
    Oudard, Stephane
    Ou, Yen-Chuan
    Sengelov, Lisa
    Saad, Fred
    Houede, Nadine
    Ostler, Peter
    Stenzl, Arnulf
    Daugaard, Gedske
    Jones, Robert
    Laestadius, Fredrik
    Ullen, Anders
    Bahl, Amit
    Castellano, Daniel
    Gschwend, Juergen
    Maurina, Tristan
    Maneval, Edna Chow
    Wang, Shaw-Ling
    Lechuga, Maria Jose
    Paolini, Jolanda
    Chen, Isan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (02) : 76 - +
  • [35] A randomized phase II cross-over study of abiraterone plus prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration resistant prostate cancer (mCRPC).
    Chi, Kim N.
    Annala, Matti
    Sunderland, Katherine
    Khalaf, Daniel
    Finch, Daygen
    Oja, Conrad D.
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Beja, Kevin
    Vandekerkhove, Gillian
    Gleave, Martin
    Wyatt, Alexander William
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Small, Eric Jay
    Lance, Raymond
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Stubbs, Andrew
    McCoy, Candice
    DeVries, Todd
    Redfern, Charles H.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [37] Multimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
    Carr, T. H.
    Adelman, C.
    Barnicle, A.
    Kozarewa, I.
    Luke, S.
    Lai, Z.
    Menon, S.
    Hollis, S.
    Dougherty, B.
    Harrington, E. A.
    Barrett, J. C.
    Goessl, C.
    Saad, F.
    Sala, N.
    Clarke, N. W.
    Hodgson, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [38] Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451)
    Heath, Elisabeth I.
    Mannuel, Heather Dorothy
    Liu, Glenn
    Lara, Primo
    Monk, J. P.
    Flaig, Thomas W.
    Zurita, Amado J.
    Vaishampayan, Ulka N.
    Stella, Philip J.
    Smith, Daryn W.
    Dobson, Kimberlee
    Hussain, Arif
    Al-Janadi, Anas
    Ivy, S. Percy
    Heilbrun, Lance K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [39] CABAZITAXEL PLUS PREDNISONE/PREDNISOLONE SIGNIFICANTLY INCREASES OVERALL SURVIVAL COMPARED TO MITOXANTRONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: FINAL RESULTS WITH UPDATED OVERALL SURVIVAL OF A MULTINATIONAL PHASE III TRIAL (TROPIC)
    Oudard, S. M.
    De Bono, J. S.
    Ozguroglu, M.
    Hansen, S.
    Machiels, J.
    Shen, L.
    Gupta, S.
    Sartor, A. O.
    ANNALS OF ONCOLOGY, 2010, 21 : 272 - 272
  • [40] Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
    Sweeney, Christopher
    Bracarda, Sergio
    Sternberg, Cora N.
    Chi, Kim N.
    Olmos, David
    Sandhu, Shahneen
    Massard, Christophe
    Matsubara, Nobuaki
    Alekseev, Boris
    Parnis, Francis
    Atduev, Vagif
    Buchschacher, Gary L., Jr.
    Gafanov, Rustem
    Corrales, Luis
    Borre, Michael
    Stroyakovskiy, Daniil
    Alves, Gustavo Vasconcelos
    Bournakis, Evangelos
    Puente, Javier
    Harle-Yge, Marie-Laurence
    Gallo, Jorge
    Chen, Geng
    Hanover, Justin
    Wongchenko, Matthew J.
    Garcia, Josep
    de Bono, Johann S.
    LANCET, 2021, 398 (10295): : 131 - 142
12345